BioSyent Valuation

Q: What is the Fair Price of RX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

RX (CA$11.98) is trading above our estimate of [[fair value]] (CA$11.78)

Is RX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RX (CA$11.98) is trading above our estimate of fair value (CA$11.78)

Significantly Below Fair Value: RX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RX?

Key metric: As RX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RX. This is calculated by dividing RX's market cap by their current earnings.
What is RX's PE Ratio?
PE Ratio	19.5x
Earnings	CA$7.11m
Market Cap	CA$138.90m

RX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.6x
Enterprise Value/EBITDA	14.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does RX's PE Ratio compare to its peers?

The above table shows the PE ratio for RX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	29.9x
MDP Medexus Pharmaceuticals	21.9x	50.2%	CA$71.5m
CPH Cipher Pharmaceuticals	16.2x	10.0%	CA$364.4m
GRIN Grown Rogue International	37.6x	n/a	CA$206.7m
WOLF Grey Wolf Animal Health	43.8x	n/a	CA$40.3m
RX BioSyent	19.5x	n/a	CA$138.9m

Price-To-Earnings vs Peers: RX is good value based on its Price-To-Earnings Ratio (19.5x) compared to the peer average (29.9x).

Price to Earnings Ratio vs Industry

How does RX's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

14 Companies	Price / Earnings	Estimated Growth	Market Cap

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: RX is good value based on its Price-To-Earnings Ratio (19.5x) compared to the North American Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is RX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	19.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RX's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.